bimekizumab-bkzx
Jump to navigation
Jump to search
Indications
- investigational drug for treatment of moderate-to-severe plaque psoriasis[1]
- treatment of hidradenitis suppurativa in adults[2] (FDA-approved Nov 2024)
Mechanism of action
- humanized lgG1 monoclonal antibody
- inhibits IL-17, IL17A & IL17F
More general terms
References
- ↑ 1.0 1.1 Bassett M Psoriasis Falls to Novel Biologic Bimekizumab brings clear or almost clear skin to vast majority of patients in phase II trial. MedPage Today. February 19, 2018 https://www.medpagetoday.com/meetingcoverage/aad/71243
Papp K, et al Dual neutralization of interleukin (IL)-17A and IL-17F with bimekizumab in moderate-to-severe psoriasis: Results from a phase 2b, randomized, double-blinded, placebo-controlled, dose-ranging study. American Academy of Dermatology (AAD) 2018 - ↑ 2.0 2.1 Bosworth T Studies Validate IL-17 as Hidradenitis Suppurativa Drug Target. Medscape. March 20, 2023 https://www.medscape.com/viewarticle/989861
- ↑ Dowd K FDA approves Bimzelx for adults with moderate to severe hidradenitis suppurativa. Healio. Nov 20, 2024 https://www.healio.com/news/dermatology/20241120/fda-approves-bimzelx-for-adults-with-moderate-to-severe-hidradenitis-suppurativa
AMA Morning Rounds. Nov 21, 2024 American Medical Association